Browse Articles

Discover research articles across all indexed journals

Complement activation and vascular complications after pediatric allogeneic hematopoietic stem cell transplantation

Scientific Reports Lilli Leimi, Kim Vettenranta, Seppo Meri Feb 27, 2025 DOI: 10.1038/s41598-025-91455-5

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

Blood Seung Kwon Koh, Hyojin Kim, Bohwa Han et al. Feb 27, 2025 DOI: 10.1182/blood.2024025673

Abstract Anti-CD19 chimeric antigen receptor (CAR)–engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges including CD19 antigen loss greatly hinder their full therapeutic potential. Here, we revealed that cotreatment with anti-CD19 monoclonal antibody enhances antitumor activity of anti-CD19 CAR-T and -NK cells. Even though the treated antibody interferes with CD19 antigen binding of CAR, it significantly induces rapid detachment of anti-CD19 CAR effector cells from target cells, facilitating improved serial killing. This reduced interaction between CAR effector cells and target cells also leads to the alleviation of CAR-mediated trogocytosis. Interestingly, cotreatment with anti-CD19 antibody reveals time-dependent effects on the antitumor activity of anti-CD19 CAR-T cells, characterized by a reduction in early T cell activation followed by sustained high activity during prolonged exposure to target cells. This temporal modulation ultimately results in enhanced antitumor potency in vivo. These findings underscore the improved therapeutic efficacy achieved by combining anti-CD19 antibody with anti-CD19 CAR-T or -NK cells against B-cell malignancies.

Comparison of accumulation rates of beta-amyloid tracers and their relationship with cognitive changes

Scientific Reports Soo Hyun Cho, Heekyoung Kang, Hongki Ham et al. Feb 27, 2025 DOI: 10.1038/s41598-025-90642-8

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

Blood François Guilhot, Rüdiger Hehlmann Feb 27, 2025 DOI: 10.1182/blood.2024026311

Abstract Long-term outcomes with tyrosine kinase inhibitors (TKIs) show that their impact on chronic myeloid leukemia (CML) is sustained as shown by 13 studies with 5- to 14-year-follow-up, and numerous shorter-term studies of newly diagnosed chronic-phase CML. Twenty-five years of imatinib (IM) treatment confirm its beneficial effect on survival and possible cure of CML. Large, randomized, academic, treatment-optimization studies have confirmed and extended the pivotal International Randomized Study on Interferon and STI571. The 3 academic trials in Germany, France, and the United Kingdom did not show benefit of the IM-interferon (IFN) combination, despite the immunomodulatory properties of IFN. Second-generation (2G) TKIs induce responses faster than IM and recognize IM-resistance mutations but do not prolong survival compared with IM. Adverse drug-related reactions (ADRs) limit the general use of 2GTKIs despite frequent but mostly mild IM-ADRs. Molecular monitoring of treatment efficacy has been established serving as an example for other neoplasms. Comorbidities, transcript type, and the negative impact of high-risk additional chromosomal abnormalities were addressed. A new prognostic score (European Treatment and Outcome Study long-term survival score) accounts for the fact that the majority of patients with CML die of other causes. Non-CML determinants of survival have been identified. Large and long-term observational studies demonstrate that progress with CML management has also reached routine care in most but not all instances. Despite merits of 2GTKIs, IM remains the preferred treatment option for CML because of its efficacy and superior safety.

The calcineurin-responsive transcription factor Crz1 regulates the expression of CMK2 via a sole CDRE site in its promoter in budding yeast

Scientific Reports Linghuo Jiang, Yiying Gu, Yongqiang Jiang et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91599-4

Novel interferon-based antimyeloma activity

Blood Arthur Bobin, Xavier Leleu Feb 27, 2025 DOI: 10.1182/blood.2024027417

Effect of color visual stimulation by colored glass lenses on postural control

Scientific Reports Wenyu Zhang, Hiroaki Takada, Manuel Hettmannsperger et al. Feb 27, 2025 DOI: 10.1038/s41598-025-88102-4

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Blood Ástrún Helga Jónsdóttir, Helga Ágústa Sigurjónsdóttir, Sigrún Thorsteinsdóttir et al. Feb 27, 2025 DOI: 10.1182/blood.2024025624

Abstract Hypercalcemia in monoclonal gammopathy of undetermined significance (MGUS) presents a clinical challenge because it may indicate progression to multiple myeloma (MM) but could also be due to a multitude of unrelated disorders. To inform the approach to this clinical challenge, we conducted a nested cohort study within the Iceland Screens, Treats, or Prevents Multiple Myeloma screening study. Of the 75 422 Icelanders aged 40 years and above who underwent screening for MGUS, we included 2546 with MGUS who were in active follow-up, including regular serum calcium measurements. In total, 191 individuals (7.5%) had hypercalcemia detected at least once, of whom 93 had persistent hypercalcemia (48.7%). MM was found in 3 participants with persistent hypercalcemia (3.2%); all had concurrent bone disease and other end-organ damage. The most common causes of hypercalcemia were primary hyperparathyroidism (56.0%) and malignancies other than MM (16.0%). In this first comprehensive study on hypercalcemia in MGUS, we observed that hypercalcemia rarely indicated MGUS progression and never in the absence of other symptoms of MM. More than half of hypercalcemia cases were transient, and the underlying causes were similar to those in the general population. We conclude that hypercalcemia in MGUS should be approached in the same way as in those without MGUS.

Reynolds rules in swarm fly behavior based on KAN transformer tracking method

Scientific Reports Qi Yang, Jiajun Ji, Ruomiao Jing et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91674-w

The evolution of treatment-free remission

Blood Timothy P. Hughes, Agnes S. M. Yong, David M. Ross Feb 27, 2025 DOI: 10.1182/blood.2024026310

Abstract One of the most remarkable achievements of the tyrosine kinase inhibitor (TKI) era has been the capacity to induce deep molecular remissions that are sustainable off therapy in patients with chronic myeloid leukemia (CML), that is, treatment-free remission (TFR). TFR was first described in a handful of patients within 3 to 4 years of imatinib approval. In 2004, TFR was tested in a small French pilot study, followed soon after by the French STIM and Australasian TWISTER studies. These early trials demonstrated that TFR was achievable but also showed that rapid relapse was equally likely. Perhaps the most critical observation was that relapsing patients could be rapidly and safely returned to deep molecular remission after restarting therapy, minimizing the risk associated with TFR attempts. Consensus criteria for TFR eligibility were established soon after those studies were reported. Over the past decade, TFR criteria have been broadened, key predictive markers of success identified, and overall safety of TFR in the wider clinical community confirmed. Despite this progress, TFR is still only achieved in a fraction of patients with CML globally. Over the next decade, the focus will be making TFR the mainstream pathway for as many patients as possible as well as scaling back the duration of therapy required. More potent, better targeted TKIs, and immune modulation will likely have a significant impact. Predictive assays should enable most patients who attempt TFR to do so with a high probability of success. Ultimately TFR should be seen as the first step on an ambitious pathway toward cure for patients with CML.

A Stable and Dependable Visual Technique for On-Site Nipah Virus Nucleic Acids Detection

Scientific Reports Wencong Chen, Li Cai, Danni Ye et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91593-w

Abstract The Nipah Virus (NiV) is a zoonotic pathogen with the mortality rate of up to 75%, recurring in Asia over the past two decades. Due to increasing the risk of human transmission mediated by various intermediate hosts such as pigs and bats, it is necessary to produce an accurate and reliable point-of-care molecular detection method for NiV field diagnosis. In this study, we designed two pairs of primers targeting the conserved G and P genes and developed a point-of-care nucleic acid detection (POC-NAD) system by integrating one-step RT-PCR, lateral flow immunoassay, and microfluidic technologies. The POC-NAD system shows high specificity and sensitivity, with a Limit of Detection (LoD) of 199.1 copies/rxn. The primers aiming to the conserved sequences enables simultaneous detection of both NiV-M and NiV-B strains. Continuous evaluation of 21 simulated clinical samples demonstrated 100% concordance with RT-PCR results. Lateral flow-based visualization improves the display time and legibility of RT-PCR results. Additionally, microfluidic chips or chambers offer disposable reagent containers and consistent PCR amplification results across various field conditions. Therefore, the diagnostic tool is suitable for real-time nucleic acid testing and NiV surveillance in resource-limited field environments.

LOX+ iCAFs in HNSCC have the potential to predict prognosis and immunotherapy responses revealed by single cell RNA sequencing analysis

Scientific Reports Xue Liu, Huibing Li, Yanjin Wang et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91036-6

Comprehensive genomics, probiotic, and antibiofilm potential analysis of Streptococcus thermophilus strains isolated from homemade and commercial dahi

Scientific Reports Aiswarya Sudheer, Debabrata Ghosh Dastidar, Gourav Ghosh et al. Feb 27, 2025 DOI: 10.1038/s41598-025-90999-w

Effects of COVID-19 related social media use on well-being

Scientific Reports Tobias Dienlin Feb 27, 2025 DOI: 10.1038/s41598-025-91385-2

Prevalence and associated risk factors of suicidal behaviors among cancer patients in a tertiary care hospital in Bangladesh

Scientific Reports Munia Yusuf Emi, Sultan Mahmud Imran, Abdullah Al Adib et al. Feb 27, 2025 DOI: 10.1038/s41598-024-84731-3

Psychometric properties of the nursing critical thinking in clinical practice questionnaire in clinical nurse educators

Scientific Reports Llúcia Benito-Aracil, Inmaculada Bonilla-Aguilar, Sergio Alonso-Fernández et al. Feb 27, 2025 DOI: 10.1038/s41598-025-90161-6

Chemical investigation of polycyclic aromatic hydrocarbon sources in an urban area with complex air quality challenges

Scientific Reports Katarzyna Szramowiat-Sala, Marta Marczak-Grzesik, Mateusz Karczewski et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91018-8

A matching design and parameter identification method of hybrid electric propulsion system

Scientific Reports Bingjie Zhu, Yingtao Zhu, Qingyang Chen et al. Feb 27, 2025 DOI: 10.1038/s41598-025-88751-5

Integration of Euclidean and path distances in hippocampal maps

Scientific Reports Loes Ottink, Naomi de Haas, Christian F. Doeller Feb 27, 2025 DOI: 10.1038/s41598-025-90504-3

Abstract The hippocampus is a key region for forming mental maps of our environment. These maps represent spatial information such as distances between landmarks. A cognitive map can allow for flexible inference of spatial relationships that have never been directly experienced before. Previous work has shown that the human hippocampus encodes distances between locations, but it is unclear how Euclidean and path distances are distinguished. In this study, participants performed an object-location task in a virtual environment. We combined functional magnetic resonance imaging with representational similarity analysis to test how Euclidean and path distances are represented in the hippocampus. We observe that hippocampal neural pattern similarity for objects scales with distance between object locations, and suggest that the hippocampus integrates Euclidean and path distances. One key characteristic of cognitive maps is their adaptive and flexible nature. We therefore subsequently modified path distances between objects using roadblocks in the environment. We found that hippocampal pattern similarity between objects adapted as a function of these changes in path distance, selectively in route learners but not in map learners. Taken together, our study supports the idea that the hippocampus creates integrative and flexible cognitive maps.

Prevalence, deaths and disability-adjusted life years due to Alzheimer’s disease and other dementias in Middle East and North Africa, 1990–2021

Scientific Reports Fatemeh Amiri, Saeid Safiri, Ali Shamekh et al. Feb 27, 2025 DOI: 10.1038/s41598-025-89899-w